MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

Rhea-AI Summary

MaxCyte (NASDAQ:MXCT) has signed a Strategic Platform License Agreement with Anocca AB for the use of MaxCyte's Flow Electroporation® technology and ExPERT™ platform. The agreement grants Anocca non-exclusive research, clinical, and commercial rights to support their TCR-T cell therapy development.

Under the agreement, MaxCyte will receive annual licensing fees and program-related revenue. The partnership aims to enhance Anocca's cell therapy manufacturing capabilities, particularly for their lead program targeting KRAS-driven advanced pancreatic cancer currently in clinical development. Anocca recently received GMP compliance certification and manufacturing license from Swedish regulators.

Positive

• New strategic licensing agreement provides recurring revenue through annual fees
• Partnership with clinical-stage company expands MaxCyte's presence in cell therapy market
• Agreement includes both clinical and commercial rights, indicating long-term revenue potential

Negative

• Non-exclusive licensing agreement limits potential competitive advantages
• Specific financial terms and revenue projections not disclosed

Insights

Biotechnology Licensing Analyst

MaxCyte secures revenue-generating licensing deal with Anocca for TCR-T therapy development using its electroporation platform.

This strategic platform licensing agreement between MaxCyte and Anocca AB represents a significant commercial validation for MaxCyte's Flow Electroporation® technology in the competitive cell therapy manufacturing space. The deal grants Anocca non-exclusive research, clinical and commercial rights to MaxCyte's technology platform in exchange for annual licensing fees and program-related revenue.

The partnership holds particular value as Anocca has already reached important development milestones, including GMP certification from Swedish regulators and advancement of its lead KRAS-targeting pancreatic cancer program into clinical trials. This suggests MaxCyte's technology will be implemented in active development programs with near-term revenue potential rather than merely preclinical applications.

For MaxCyte investors, this agreement follows the company's established business model of securing technology licenses with biotech companies developing next-generation cell therapies. The non-viral gene editing capabilities of MaxCyte's platform are particularly valuable for TCR-T development, as they enable precise cell engineering without viral vector limitations or safety concerns. This positions MaxCyte to capture value from the growing TCR-T therapy segment.

While financial terms weren't disclosed, MaxCyte typically structures these agreements with upfront fees, annual payments that scale with clinical progression, and commercial milestones/royalties. The multi-program nature of Anocca's "deep pipeline" suggests this could become a substantial revenue contributor if programs advance successfully through clinical development.

MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapies

ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced the signing of a Strategic Platform License Agreement (SPL) with Anocca AB, a leading, clinical stage T-cell immunotherapy company. Anocca AB will deploy MaxCyte’s Flow Electroporation^® technology and ExPERT™ platform to support the scalable development and manufacturing of its deep pipeline of T-cell receptor engineered T-cell (TCR-T) cell therapies.

Under the SPL, Anocca AB obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation^® technology and ExPERT™ platform. In return, MaxCyte is entitled to receive annual licensing fees and program-related revenue.

“We’re proud to partner with Anocca as they advance the development of TCR-T therapeutics through the clinic,” said Maher Masoud, President and CEO of MaxCyte. “We look forward to supporting Anocca with our globally supported, regulatory-proven platform and technical expertise to accelerate clinical manufacturing and cell engineering processes. Our ExPERT™ platform delivers the robust scalability and flexibility needed to power high-performance, non-viral gene editing workflows across Anocca’s diverse therapeutic pipeline.”

Anocca recently received GMP compliance certification and a manufacturing license from Swedish regulators for its cell therapy production facility, and its lead program, targeting mutant KRAS-driven advanced pancreatic cancer, is in clinical development. With the addition of MaxCyte’s ExPERT™ platform, Anocca acquires a high-quality, scalable, technology platform to enhance its ability to deliver gene-edited cell therapies.

About MaxCyte
At MaxCyte^®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation^® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we’ve been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. Specifically, there is no assurance that MaxCyte will receive additional program-related revenue or other revenue under this SPL.

Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 8, 2025. These documents are available through the Investor Menu, Financials section, under “SEC Filings” on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com    

US Media Relations
Oak Street Communications
Kristen White
+1 415-608-6060
kristen@oakstreetcommunications.com 

FAQ

What is the new licensing agreement between MaxCyte (MXCT) and Anocca AB?

MaxCyte has signed a Strategic Platform License Agreement with Anocca AB, granting them non-exclusive rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform for TCR-T cell therapy development.

How will MaxCyte (MXCT) generate revenue from the Anocca partnership?

MaxCyte will receive annual licensing fees and program-related revenue from Anocca's use of their technology platform.

What is Anocca's lead program using MaxCyte's technology?

Anocca's lead program targets mutant KRAS-driven advanced pancreatic cancer and is currently in clinical development.

What regulatory approvals has Anocca received for cell therapy production?

Anocca has received GMP compliance certification and a manufacturing license from Swedish regulators for its cell therapy production facility.

How will MaxCyte's ExPERT platform benefit Anocca's development process?

The ExPERT™ platform will provide Anocca with robust scalability and flexibility for high-performance, non-viral gene editing workflows across their therapeutic pipeline.